source
- Healthcare systems lag behind rapid expansion of GLP-1 therapies, raising care and trust challengesGLP-1 drugs have demonstrated that pharmacological treatment can effectively reduce obesity, and regulators have now approved them for additional uses such as cardiovascular risk reduction, metabol…
- Compass eyes J&J’s Spravato playbook for upcoming psychedelic drug COMP360 launchCompass executives told BioPharma Dive that, if the FDA approves their treatment, they plan to follow the commercial strategy Johnson & Johnson used for its ketamine spray Spravato. When Spravato…